These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 7907608)

  • 61. [Expression and clinical significance of the AgNOR and PCNA in Barrett's adenocarcinoma and its precancerous lesions].
    Li H; Yao S; Stuart R
    Zhonghua Zhong Liu Za Zhi; 1995 Jul; 17(4):286-8. PubMed ID: 7587897
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Overexpression of the p53 tumor suppressor gene product in esophageal and gastric carcinomas.
    Fléjou JF; Muzeau F; Potet F; Lepelletier F; Fékété F; Hénin D
    Pathol Res Pract; 1994 Dec; 190(12):1141-8. PubMed ID: 7540752
    [TBL] [Abstract][Full Text] [Related]  

  • 63. bcl-2 protein expression in the Barrett's metaplasia-dysplasia-carcinoma sequence.
    Goldblum JR; Rice TW
    Mod Pathol; 1995 Oct; 8(8):866-9. PubMed ID: 8552577
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Activation of Akt is increased in the dysplasia-carcinoma sequence in Barrett's oesophagus and contributes to increased proliferation and inhibition of apoptosis: a histopathological and functional study.
    Beales IL; Ogunwobi O; Cameron E; El-Amin K; Mutungi G; Wilkinson M
    BMC Cancer; 2007 Jun; 7():97. PubMed ID: 17559672
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Proliferating cell nuclear antigen in oesophageal diseases; correlation with transforming growth factor alpha expression.
    Jankowski J; McMenemin R; Yu C; Hopwood D; Wormsley KG
    Gut; 1992 May; 33(5):587-91. PubMed ID: 1351861
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Time gated fluorescence spectroscopy in Barrett's oesophagus.
    Ortner MA; Ebert B; Hein E; Zumbusch K; Nolte D; Sukowski U; Weber-Eibel J; Fleige B; Dietel M; Stolte M; Oberhuber G; Porschen R; Klump B; Hörtnagl H; Lochs H; Rinneberg H
    Gut; 2003 Jan; 52(1):28-33. PubMed ID: 12477755
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus.
    Koss K; Harrison RF; Gregory J; Darnton SJ; Anderson MR; Jankowski JA
    J Clin Pathol; 2004 Nov; 57(11):1156-9. PubMed ID: 15509675
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Treatment Outcomes of Endoscopic Submucosal Dissection for Adenocarcinoma Originating from Long-Segment Barrett's Esophagus versus Short-Segment Barrett's Esophagus.
    Shimizu T; Fujisaki J; Omae M; Yamasaki A; Horiuchi Y; Ishiyama A; Yoshio T; Hirasawa T; Yamamoto Y; Tsuchida T
    Digestion; 2018; 97(4):316-323. PubMed ID: 29539629
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Gastric metaplasia of the proximal esophagus associated with esophageal adenocarcinoma and Barrett's esophagus: what is the connection? Inlet patch revisited.
    Malhi-Chowla N; Ringley RK; Wolfsen HC
    Dig Dis; 2000; 18(3):183-5. PubMed ID: 11279338
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effect of Barrett's esophagus surveillance on esophageal preservation, tumor stage, and survival with esophageal adenocarcinoma.
    Grant KS; DeMeester SR; Kreger V; Oh D; Hagen JA; Chandrasoma P; DeMeester TR
    J Thorac Cardiovasc Surg; 2013 Jul; 146(1):31-7. PubMed ID: 23312980
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Barrett's esophagus: a retrospective analysis of 13 years surveillance.
    Switzer-Taylor V; Schlup M; Lübcke R; Livingstone V; Schultz M
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1362-7. PubMed ID: 18205769
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.
    Vallböhmer D; Peters JH; Oh D; Kuramochi H; Shimizu D; Demeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; DeMeester TR; Danenberg P
    Surgery; 2005 Oct; 138(4):701-6; discussion 706-7. PubMed ID: 16269299
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas.
    Wilson KT; Fu S; Ramanujam KS; Meltzer SJ
    Cancer Res; 1998 Jul; 58(14):2929-34. PubMed ID: 9679948
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry.
    O'Connor JB; Falk GW; Richter JE
    Am J Gastroenterol; 1999 Aug; 94(8):2037-42. PubMed ID: 10445525
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Expression of proliferating cell nuclear antigen (PC10), p53 protein and c-erbB-2 in renal adenocarcinoma.
    Lipponen P; Eskelinen M; Hietala K; Syrjänen K; Gambetta RA
    Int J Cancer; 1994 Apr; 57(2):275-80. PubMed ID: 7908898
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Immunohistochemical demonstration of c-erbB-2 oncoprotein in gastric adenocarcinoma: comparison of cryostat and paraffin wax sections and effect of fixation.
    Chiu KY; Loke SL; Ho FC
    J Clin Pathol; 1994 Feb; 47(2):117-21. PubMed ID: 7907612
    [TBL] [Abstract][Full Text] [Related]  

  • 77. C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators.
    Travis A; Pinder SE; Robertson JF; Bell JA; Wencyk P; Gullick WJ; Nicholson RI; Poller DN; Blamey RW; Elston CW; Ellis IO
    Br J Cancer; 1996 Jul; 74(2):229-33. PubMed ID: 8688326
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Immunohistochemical study of c-erbB-2 proto-oncogene product in prostatic cancer].
    Kokuho M; Yoshiki T; Hamaguchi A; Okada Y; Tomoyoshi T; Higuchi K
    Nihon Hinyokika Gakkai Zasshi; 1993 Oct; 84(10):1872-8. PubMed ID: 7902885
    [TBL] [Abstract][Full Text] [Related]  

  • 79. c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma--an immunocytochemical study.
    Gasparini G; Gullick WJ; Maluta S; Dalla Palma P; Caffo O; Leonardi E; Boracchi P; Pozza F; Lemoine NR; Bevilacqua P
    Eur J Cancer; 1994; 30A(1):16-22. PubMed ID: 7908213
    [TBL] [Abstract][Full Text] [Related]  

  • 80. C-erbB-2 oncoprotein immunostaining in serous effusions.
    Ascoli V; Scalzo CC; Nardi F
    Cytopathology; 1993; 4(4):207-18. PubMed ID: 8104524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.